Similar articles for PMID: 25347122

Year	Number of Results
2007	1
2008	1
2009	2
2010	13
2011	9
2012	10
2013	10
2014	3
2015	4
2016	4
2017	5
2018	4
2019	3
2020	14
2021	10
2022	7
2023	8
2024	0

1

Standard of care and promising new agents for triple negative metastatic breast cancer.

Mancini P, Angeloni A, Risi E, Orsi E, Mezi S. Mancini P, et al. Cancers (Basel). 2014 Oct 24;6(4):2187-223. doi: 10.3390/cancers6042187. Cancers (Basel). 2014. PMID: 25347122 Free PMC article. Review.

2

Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer.

Sayed-Ahmed MM, Hafez MM, Al-Shabanah OA, Al-Rejaie SS, Aleisa AM, Al-Yahya AA, Alsheikh A, Al Diab AI, Al-Akeely MH. Sayed-Ahmed MM, et al. Tumori. 2013 Jul-Aug;99(4):545-54. doi: 10.1177/030089161309900418. Tumori. 2013. PMID: 24326846

3

Targeted Therapies in Triple-Negative Breast Cancer.

Marmé F, Schneeweiss A. Marmé F, et al. Breast Care (Basel). 2015 Jul;10(3):159-66. doi: 10.1159/000433622. Epub 2015 Jun 24. Breast Care (Basel). 2015. PMID: 26557820 Free PMC article. Review.

4

The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.

Papadimitriou M, Mountzios G, Papadimitriou CA. Papadimitriou M, et al. Cancer Treat Rev. 2018 Jun;67:34-44. doi: 10.1016/j.ctrv.2018.04.010. Epub 2018 May 2. Cancer Treat Rev. 2018. PMID: 29753961 Review.

5

Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.

Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, Tang-Tan AM, Guye ML, Chang DZ, Winston JS, Samli B, Jansen RJ, Petricoin EF, Goetz MP, Bear HD, Tang AH. Gupta GK, et al. Cancers (Basel). 2020 Aug 24;12(9):2392. doi: 10.3390/cancers12092392. Cancers (Basel). 2020. PMID: 32846967 Free PMC article. Review.

6

Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.

Park Y, Moriyama A, Kitahara T, Yoshida Y, Urita T, Kato R. Park Y, et al. Anticancer Agents Med Chem. 2012 Jul;12(6):672-7. doi: 10.2174/187152012800617759. Anticancer Agents Med Chem. 2012. PMID: 22263793 Review.

7

Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.

Mehlich D, Marusiak AA. Mehlich D, et al. Cancer Lett. 2022 Oct 28;547:215775. doi: 10.1016/j.canlet.2022.215775. Epub 2022 Jun 3. Cancer Lett. 2022. PMID: 35667515 Review.

8

Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer.

Mezi S, Botticelli A, Pomati G, Cerbelli B, Scagnoli S, Amirhassankhani S, d'Amati G, Marchetti P. Mezi S, et al. Cancers (Basel). 2021 Mar 3;13(5):1080. doi: 10.3390/cancers13051080. Cancers (Basel). 2021. PMID: 33802438 Free PMC article. Review.

9

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.

Li Y, Zhan Z, Yin X, Fu S, Deng X. Li Y, et al. Front Oncol. 2021 Oct 28;11:731535. doi: 10.3389/fonc.2021.731535. eCollection 2021. Front Oncol. 2021. PMID: 34778045 Free PMC article. Review.

10

Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.

Tong L, Yu X, Wang S, Chen L, Wu Y. Tong L, et al. Breast Cancer (Dove Med Press). 2023 Aug 24;15:647-658. doi: 10.2147/BCTT.S426121. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 37644916 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year